<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83031">
  <stage>Registered</stage>
  <submitdate>1/08/2008</submitdate>
  <approvaldate>8/01/2009</approvaldate>
  <actrnumber>ACTRN12609000011280</actrnumber>
  <trial_identification>
    <studytitle>Sub-chronic administration of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers: drug initiation effects and the role of serotonin in experimental anxiety.</studytitle>
    <scientifictitle>The effect in healthy volunteers of administration of the selective serotonin reuptake inhibitor escitalopram (10 mg/day for 3 weeks) vs. placebo on drug initiation effects and experimentally-induced anxiety.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>anxiety</healthcondition>
    <healthcondition>selective serotonin reuptake inhibitor (SSRI) initiation effects</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Anxiety</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>escitalopram (10 mg/day for 3 weeks, oral)
tryptophan depletion</interventions>
    <comparator>placebo (sugar capsule, 3 weeks, oral)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in the Spielberger State Anxiety Inventory in the placebo and escitalopram groups</outcome>
      <timepoint>pre and post tryptophan depletion</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Visual Analogue Scale scores (anxiety, nervous) in the placebo and escitalopram groups</outcome>
      <timepoint>pre and post tryptophan depletion</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Spielberger state anxiety Inventory</outcome>
      <timepoint>pre-drug, 3 days, 1 week, 2 weeks and 3 weeks post drug initiation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>healthy volunteer
no current or previous history of anxiety, depression or mental illness</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>current or past mental illness
current or past use of SSRI medication
pregnant/breastfeeding
serious medical condition
history of head injury 
history of drug abuse/dependence</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants are screened by study doctors.  Once deemed eligible to participate, they will be assigned a study number that corresponds to study medication bottles.</concealment>
    <sequence>placebo and escitalopram order randomly assigned in blocks using a random number generator (www.random.org)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>10/08/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>28</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Western Australia</primarysponsorname>
    <primarysponsoraddress>35 Stirling Hwy
Nedlands, WA, 6009</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Western Australia Small Grants Scheme 2007</fundingname>
      <fundingaddress>35 Stirling Hwy
Nedlands, WA, 6009</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to investigate whether the effect of selective serotonin reuptake inhibitors seen when used to treat anxiety are related to the drug, or to the fact that the people have an anxiety disorder.  We expect that we will see "jitteriness" when healthy volunteers start taking the medication, and that the medication will reduce anxiety brought on  by an experimental challenge in people who do not have an anxiety disorder.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>UWA HREC</ethicname>
      <ethicaddress>35 Stirling Hwy
Nedlands, WA, 6009</ethicaddress>
      <ethicapprovaldate>26/05/2008</ethicapprovaldate>
      <hrec>RA/1/4/1984</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Sean Hood</name>
      <address>School of Psychiatry and Clinical Neurosciences
35 Stirling Hwy
Nedlands, WA, 6009</address>
      <phone>+61 8 9346 2393</phone>
      <fax />
      <email>sean.hood@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sean Hood</name>
      <address>School of Psychiatry and Clinical Neurosciences
35 Stirling Hwy
Nedlands, WA, 6009</address>
      <phone>+61 8 9346 2393</phone>
      <fax />
      <email>sean.hood@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Dana Hince</name>
      <address>School of Psychiatry and Clinical Neurosciences
35 Stirling Hwy
Nedlands, WA, 6009</address>
      <phone />
      <fax />
      <email>dana.hince@uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>